MRNA - Moderna - Stock Forecast

Healthcare - Sector
Coverage Profile Performance Price Targets & Ratings Chart Insider Trading

MRNA is currently covered by 19 analysts with an average price target of $116.3. This is a potential upside of $12.51 (12.05%) from yesterday's end of day stock price of $103.79.

Moderna's activity chart (see below) currently has 292 price targets and 268 ratings on display. The stock rating distribution of MRNA is 36.92% HOLD, 52.31% BUY and 10.77% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 74.02% with an average time for these price targets to be met of 90.62 days.

Highest price target for MRNA is $231, Lowest price target is $68, average price target is $116.3.

Most recent stock forecast was given by LUCA ISSI from RBC on 28-Mar-2024. First documented stock forecast 02-Jan-2019.

What is MRNA or Moderna?

A team of scientists, including Derrick Rossi and Noubar Afeyan, founded Moderna, a biotechnology company in 2010 with the main goal of developing new therapies and vaccines using mRNA technology. Moderna has become one of the most famous and successful biotech companies globally since its establishment. In this article, we’ll explore Moderna’s breakthroughs, products, and services, and assess its success so far.

What Made Moderna Famous?

Moderna made a breakthrough in 2017 when it developed a personalized cancer vaccine that uses mRNA to stimulate the immune system to attack cancer cells. The vaccine is currently in clinical trials and has shown promising results. Moderna has also made significant strides in developing mRNA therapeutics and vaccines for various diseases, including COVID-19, cancer, heart disease, and rare genetic disorders.

What are the famous products or services of Moderna?

Respiratory vaccines

Moderna has developed vaccines for respiratory illnesses such as COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3. These vaccines work by utilising messenger RNA (mRNA) technology to instruct cells to produce proteins that trigger an immune response against the virus.

Latent vaccines

Moderna has also developed vaccines for latent viruses such as cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus (HIV). These vaccines aim to prevent infections from viruses that can remain dormant in the body and reactivate later.

Public health vaccines

Moderna has developed vaccines for public health threats such as Zika and Nipah viruses. These vaccines utilise mRNA technology to trigger an immune response against the viruses.

Systemic secreted and cell surface therapeutics

Moderna is instructing cells to produce therapeutic proteins that can be secreted or expressed on the cell surface through a range of therapies that use mRNA technology. These therapies have the potential to treat a wide range of diseases, including rare genetic diseases and cancer.

Cancer vaccines

Moderna is developing personalised cancer vaccines that target specific mutations in an individual’s cancer cells. The company is developing vaccines that target the KRAS protein, which cancer cells often mutate. Additionally, Moderna is working on checkpoint vaccines that aim to boost the immune system’s ability to attack cancer cells.

Intratumoral immuno-oncology products

Moderna is developing therapies that can be injected directly into tumours to trigger an immune response against cancer cells.

Localised regenerative therapeutics

Moderna is developing therapies that use mRNA technology to instruct cells to produce proteins that promote tissue regeneration. These therapies have the potential to treat a range of conditions, including heart disease.

Systemic intercellular therapeutics

Moderna is developing therapies that use mRNA technology to target cells within the body and instruct them to produce therapeutic proteins. These therapies have the potential to treat a range of diseases, including rare genetic diseases and cancer.

Inhaled pulmonary therapeutics

Moderna is developing therapies that can be inhaled to treat respiratory diseases such as cystic fibrosis. These therapies utilise mRNA technology to instruct cells in the lungs to produce therapeutic proteins.

Assessing Moderna’s Success So Far

Moderna’s cutting-edge mRNA technology has enabled the company to develop groundbreaking therapies and vaccines, leading to its success. The company’s revenue surged in recent years, driven by its COVID-19 vaccine, which has been authorized for emergency use in over 50 countries. In 2021, the company reported revenue of $19.2 billion, up from just $60 million in 2019. Sales of the COVID-19 vaccine generated the vast majority of this revenue.
Moderna’s robust pipeline of other mRNA therapeutics and vaccines in development also fueled its success. The company forged strategic alliances with medical names such as AstraZeneca PLC, Merck & Co., Vertex Pharmaceuticals Incorporated, and Carisma Therapeutics, among others, to further its impact on global health initiatives. Moderna’s partnerships include licences from Defense Advanced Research Projects Agency (DARPA), Biomedical Advanced Research Development Authority (BARDA) Institute for Life Changing Medicines, and even a partnership with The Bill & Melinda Gates Foundation.
Moderna’s COVID-19 vaccine played a crucial role in fighting the pandemic. The company used its mRNA technology to create a vaccine that is highly effective and has a good safety profile. Moderna’s vaccine was authorized for emergency use by the US FDA in December 2020 and has since been used to vaccinate millions of people worldwide.
In addition to its COVID-19 vaccine, Moderna is developing vaccines for other infectious diseases such as Zika and cytomegalovirus, as well as mRNA therapeutics for a variety of diseases, including cancer, heart disease, and rare genetic disorders.

Currently out of the existing stock ratings of MRNA, 24 are a HOLD (36.92%), 34 are a BUY (52.31%), 7 are a SELL (10.77%).

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

91

$-14.09 (-13.41%)

82

1 months 26 days ago

1/2 (50%)

$-5.46 (-5.66%)

12

1.58

Buy

120

$14.91 (14.19%)

80

3 months 2 days ago

1/2 (50%)

$17.84 (17.46%)

15

8.2

Buy

142

$36.91 (35.12%)

3 months 16 days ago

7/8 (87.5%)

$29.5 (26.22%)

97

17.47

Sell

90

$-15.09 (-14.36%)

140

4 months 17 days ago

4/4 (100%)

$10.17 (12.74%)

74

5.67

115

$9.91 (9.43%)

123

5 months 12 days ago

25/34 (73.53%)

$42.93 (59.57%)

134

5.96

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is MRNA (Moderna) average time for price targets to be met?

On average it took 90.62 days on average for the stock forecasts to be realized with a an average price target met ratio 74.02

Which analyst has the current highest performing score on MRNA (Moderna) with a proven track record?

NICK ABBOTT

Which analyst has the most public recommendations on MRNA (Moderna)?

Nick Abbott has 7 price targets and 4 ratings on MRNA

Which analyst is the currently most bullish on MRNA (Moderna)?

Leah Rush Cann with highest potential upside - $329.6

Which analyst is the currently most reserved on MRNA (Moderna)?

Anthony Paolone with lowest potential downside - -$51.85

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?